MediciNova, Inc. announced that a Phase I clinical trial to evaluate MN-166 (ibudilast) 10 mg intravenous (IV) infusion in healthy volunteers (HV) has been completed. The trial results yielded encouraging findings as MN-166 (ibudilast) was delivered intravenously to HV with a favorable safety profile and was well tolerated. There were no concerning adverse events (AEs), all reported AEs were mild, all study drug-related AEs were mild, and none of the AEs were unexpected.

This IV formulation of MN-166 (ibudilast) is being developed for inflammatory disorders, specifically prevention of acute respiratory distress syndrome (ARDS), sepsis, and cytokine release syndrome. In addition, the newly developed IV formulation will provide another option for health care providers to treat hospitalized patients and patients who are unable to swallow capsules.